BriaCell to Showcase Strong Anti-Cancer Effects of Bria-OTS+™ in Breast and Prostate Cancer Studies
Bria-OTS+ Platform Presentation: BriaCell Therapeutics will present its next generation Bria-OTS+ platform, showcasing its strong anti-cancer activity and immune system engagement at the SITC Annual Meeting on November 7, 2025.
Clinical Trials and Funding: The lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have completed GMP manufacturing and are set for clinical trials, with Bria-PROS+ receiving a $2 million NCI SBIR award to support its evaluation.
Innovative Immunotherapy: Bria-OTS+ is an advanced immunotherapy platform designed to enhance immune engagement through multiple immune-activating cytokines and co-stimulatory molecules, building on the positive results of its predecessor, Bria-OTS™.
Company Overview: BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care, with more information available on their website.
Trade with 70% Backtested Accuracy
Analyst Views on BCTXW
No data
About the author
BRIACELL THERAPEUTICS CORP TO ALLOCATE UP TO $3 MILLION FOR BRIAPRO RESEARCH AND DEVELOPMENT
Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.
Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.
BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
BRIACELL AND BRIAPRO SIGN ASSET PURCHASE AGREEMENT FOR EXCLUSIVE LICENSE OF SOLUBLE CD80
Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.
Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.
Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.
Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.
Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.
BRIACELL THERAPEUTICS CORP TO ALLOCATE UP TO $3 MILLION FOR BRIAPRO RESEARCH AND DEVELOPMENT
Funding Announcement: BRIACELL Therapeutics Corp has announced a funding initiative to provide up to $3 million for research and development (R&D) purposes.
Purpose of Funding: The funding is aimed at advancing the company's therapeutic programs and enhancing its research capabilities.
BRIACELL THERAPEUTICS CORP - BRIAPRO TO REMIT 2% ROYALTIES TO UMBC AFTER COMMERCIALIZATION
Royalty Agreement: BRIACELL THERAPEUTICS CORP has agreed to pay 2% royalties to TUMBC upon the commercialization of its products.
Commercialization Focus: The agreement emphasizes the importance of commercializing BRIACELL's therapeutic products in collaboration with TUMBC.
BRIACELL AND BRIAPRO SIGN ASSET PURCHASE AGREEMENT FOR EXCLUSIVE LICENSE OF SOLUBLE CD80
Agreement Overview: A new agreement has been reached for the purchase of exclusive soluble CD80 licenses.
Parties Involved: The agreement involves BRIACELL and a partner entity, indicating a strategic collaboration in the biotech sector.
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
BriaCell Showcases Strong Anti-Cancer Effects of Bria-OTS+™ at SITC 2025
Bria-OTS+ Platform Overview: BriaCell Therapeutics has showcased its next-generation Bria-OTS+ platform, which demonstrates rapid and durable anti-cancer activity by engaging both innate and adaptive immune responses in preclinical models.
Preclinical Findings: The platform's lead candidates, Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer, have shown strong immune activation and sustained anti-cancer responses, indicating potential for prolonged clinical benefits.
Broad Applicability: The positive results from Bria-BRES+ and Bria-PROS+ suggest the Bria-OTS+ platform could be expanded to treat other solid tumors, highlighting its ability to generate potent immune responses across various cancer types.
Future Clinical Trials: BriaCell plans to confirm these preclinical findings in upcoming Phase 1/2a clinical studies, with Bria-PROS+ supported by a $2 million National Cancer Institute award.
